Belgium-headquartered Janssen, one of the pharmaceutical companies of US pharma giant Johnson & Johnson, and developer of the first single-dose COVID-19 vaccine, has signed a Memorandum of Understanding (MoU) with the Ministry of Investment of Saudi Arabia (MISA) to partner and co-develop the Kingdom’s healthcare and life sciences ecosystem over the next five years.

The company said in a statement on Tuesday that the partnership framework spans four workstreams that include enhancing the business environment and funding, supporting the data and clinical trials ecosystem, enabling human capital development and boosting innovation in the private sector.

The MoU was signed by Jamie Phares, Managing Director, Janssen GCC and Faysal Hamza, Deputy Minister at the Ministry of Investment.

(Writing by SA Kader; Editing by Anoop Menon)

(anoop.menon@refinitiv.com)

Disclaimer: This article is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Read our full disclaimer policy here.

 

© ZAWYA 2021